N/A
Manufactured by Padagis Israel Pharmaceuticals Ltd
11,162 FDA adverse event reports analyzed
Last updated: 2026-04-14
BRIMONIDINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Padagis Israel Pharmaceuticals Ltd. The most commonly reported adverse reactions for BRIMONIDINE include TREATMENT FAILURE, DRUG INEFFECTIVE, HYPERSENSITIVITY, OFF LABEL USE, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BRIMONIDINE.
Out of 7,411 classified reports for BRIMONIDINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 11,162 FDA FAERS reports that mention BRIMONIDINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TREATMENT FAILURE, DRUG INEFFECTIVE, HYPERSENSITIVITY, OFF LABEL USE, FATIGUE, INTRAOCULAR PRESSURE INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Padagis Israel Pharmaceuticals Ltd in connection with BRIMONIDINE. Always verify the specific product and NDC with your pharmacist.